A randomized open label multicenter phase II study of first line therapy with sorafenib in association with IL-2 [interleukin-2] vs sorafenib alone in patients with unresectable and/or metastatic renal cell carcinoma

Trial Profile

A randomized open label multicenter phase II study of first line therapy with sorafenib in association with IL-2 [interleukin-2] vs sorafenib alone in patients with unresectable and/or metastatic renal cell carcinoma

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Sep 2013

At a glance

  • Drugs Sorafenib (Primary) ; Interleukin-2
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms ROSORC
  • Most Recent Events

    • 31 May 2013 Overall survival results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
    • 16 Feb 2013 Results presented at the 2013 Genitourinary Cancers Symposium with focus on overall survival results.
    • 29 Mar 2011 Primary endpoint 'Progression free survival duration' has not been met according to results published in the British Journal of Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top